期刊文献+

HPLC法测定注射用兰索拉唑中主药及有关物质的含量 被引量:8

Determination of Main Components and the Related Substances in Lansoprazole for Injection by HPLC
原文传递
导出
摘要 目的:建立以高效液相色谱法测定注射用兰索拉唑中主药及有关物质含量的方法。方法:色谱柱为Shim-packC18,流动相为甲醇-水-三乙胺-磷酸(620∶380∶5∶1·5),流速为1mL·min-1,检测波长为284nm,进样量为20μL。结果:兰索拉唑检测浓度的线性范围为16~320μg·mL-l(r=0·9999);平均回收率为100·0%(RSD=1·08%,n=9);有关物质含量均为0·147%。结论:该方法简便、快速、准确、重现性好,适用于该制剂的质量控制。 OBJECTIVE: To establish a RP-HPLC method for the determination of Lansoprazole and the related substances in Lansoprazole for injection. METHODS: The separation was performed on Shim-pack C18 column. The mobile phase consisted of methanol- water- triethylamine -phosphoric acid (620∶380∶5∶1.5) with a flow rate of 1.0mL·min-1,detection wavelength of 284 nm and sample size of 20μL. RESULTS: The calibration curve was linear in the range of 16~320μg·mL-1(r=0.999 9). The average recovery was 100.0%(RSD=1.08%,n=9)...
作者 浦锡娟 何峰
出处 《中国药房》 CAS CSCD 北大核心 2007年第13期1013-1014,共2页 China Pharmacy
关键词 高效液相色谱法 兰索拉唑 有关物质 含量 HPLC Lansoprazole Related substances Content
  • 相关文献

参考文献1

二级参考文献15

  • 1GHANNOUM MA,KUHN DM.Voriconazole-better chances for patients with invasive mycoses[J].Eur J Med Res,2002,7 (5) :242-256. 被引量:2
  • 2PFALLER MA,DIEKEMA DJ,JONES RN,et al. International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 19 被引量:1
  • 3ESPINEL-INGROFF A.In vitro activity of the new triazole voriconazole(UK-109,496)against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens[J].J Clin Microbiol, 1998,36 ( 1 ) :198-202. 被引量:1
  • 4ESPINEL-INGROFF A.In vitro fungicidal activities of voriconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi[J].J Clin MicrobioI,2001,39 (3) :954-958. 被引量:1
  • 5CARRILLO AJ,GUARRO J.In vitro activities of four novel triazoles against Scedosporium spp[J].Antimicrob Agents Chemother, 2001,45 ( 7 ) :2151-2153. 被引量:1
  • 6PURKINS L,WOOD N,GHAHRAMANI P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].Antimicrob Agents Chemother, 2002,46 (8) :2546-2553. 被引量:1
  • 7VENKATARAMANAN R, ZANG S,GAYOWSKI T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes[J].Antimicrob Agents Chemother,2002,46 (9) :3091-3093. 被引量:1
  • 8ROMERO A J, POGAMP PL,NILSSON LG, et al. Effect of voriconazole on the pharmacokinetics of cycrosporine in renal transplant patients[J].J Clin Pharmacol Ther,2002,71 (4) :226-234. 被引量:1
  • 9DENNING DW, RIBAUD P, MILPIED N,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J].Clin Infect Dis,2002,34 (5) :563-571. 被引量:1
  • 10HEBRECHT R,DENNING DW, PATTERSON TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347 (6) :408-415. 被引量:1

共引文献38

同被引文献76

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部